Omada Health, Inc.
Business
Omada Health delivers virtual, evidence-based chronic disease management and prevention programs through a human-led, technology-enabled care model combining dedicated Care Teams with AI-powered tools. The company offers cardiometabolic programs (diabetes prevention, diabetes management, hypertension, and cholesterol), musculoskeletal (MSK) physical therapy, and GLP-1 medication support and prescribing services. Omada distributes through direct sales to employers, health plans, PBMs, and health systems, as well as through channel partners, serving over 886,000 enrolled members as of December 2025.
Summary from 10-K filed 2026-07-01
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Total revenue | 260 | 170 | 123 | |
| Total cost of revenue | 89 | 67 | 53 | |
| Gross profit | 171 | 103 | 70 | |
| Research and development | 41 | 36 | 34 | |
| Sales and marketing | 90 | 68 | 66 | |
| General and administrative | 52 | 43 | 36 | |
| Total operating expenses | 183 | 147 | 136 | |
| Operating loss | −12 | −44 | −66 | |
| Interest expense | −3 | −5 | −5 | |
| Interest income | 5 | 805,000 | 6 | |
| Loss on debt extinguishment | −2 | 0 | −2 | |
| Change in fair value of warrants | −1 | 218,000 | −1 | |
| Total other expense, net | −806,000 | −3 | −2 | |
| Loss before provision for income taxes | −13 | −47 | −68 | |
| Provision for income taxes | 0 | 0 | 0 | |
| Net loss and comprehensive loss | −13 | −47 | −68 | |
| Net loss and comprehensive loss | −13 | −47 | −68 | |
| Basic (in dollars per share) | −0.35 | −6.11 | −9.52 | |
| Diluted (in dollars per share) | −0.35 | −6.11 | −9.52 | |
| Basic (in shares) | 37 | 8 | 7 | |
| Diluted (in shares) | 37 | 8 | 7 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 222 | 76 | — | — | |
| Accounts receivable, net | 35 | 23 | — | — | |
| Inventory | 4 | 3 | — | — | |
| Deferred commissions, current | 4 | 3 | — | — | |
| Contract assets | 638,000 | 502,000 | — | — | |
| Prepaid expenses and other current assets | 8 | 7 | — | — | |
| Total current assets | 273 | 113 | — | — | |
| Property and equipment, net | 8 | 6 | — | — | |
| Operating lease right-of-use asset | 0 | 447,000 | — | — | |
| Deferred commissions, non-current | 9 | 9 | — | — | |
| Intangible assets, net | 2 | 4 | — | — | |
| Goodwill | 13 | 13 | — | — | |
| Other assets | 165,000 | 5 | — | — | |
| Total assets | 305 | 151 | — | — | |
| Accounts payable | 10 | 4 | — | — | |
| Accrued expenses and other current liabilities | 40 | 30 | — | — | |
| Operating lease liability, current | 0 | 415,000 | — | — | |
| Deferred revenue | 25 | 20 | — | — | |
| Total current liabilities | 76 | 54 | — | — | |
| Long term debt | 0 | 30 | — | — | |
| Warrant liabilities, non-current | 0 | 2 | — | — | |
| Other liabilities, non-current | 0 | 285,000 | — | — | |
| Total liabilities | 76 | 86 | — | — | |
| Commitments and contingencies (Note 7) | — | — | — | — | |
| Redeemable convertible preferred stock, $0.001 par value per share; no shares and 120,689 shares authorized as of December 31, 2025 and December 31, 2024, respectively; no shares and 118,219 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively; aggregate liquidation preference of $0 and $455,588 as of December 31, 2025 and December 31, 2024, net of issuance costs | 0 | 449 | 449 | 449 | |
| Common stock, $0.001 par value per share; 750,000 and 181,500 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 58,429 and 8,157 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 58,000 | 8,000 | — | — | |
| Additional paid-in capital | 686 | 60 | — | — | |
| Accumulated deficit | −457 | −444 | — | — | |
| Total stockholders equity (deficit) | 230 | −384 | −350 | −293 | |
| Total liabilities, redeemable convertible preferred stock and stockholders equity (deficit) | 305 | 151 | — | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Depreciation and amortization | 5 | 5 | 4 | |
| Share-based compensation | 13 | 9 | 9 | |
| Loss on disposal of property and equipment | 8,000 | 2,000 | 151,000 | |
| Amortization of debt issuance costs | 285,000 | 389,000 | 416,000 | |
| Non-cash operating lease expense | 447,000 | 728,000 | 683,000 | |
| Provision for credit losses | 1 | 2 | 452,000 | |
| Amortization of deferred commissions | 3 | 3 | 2 | |
| Accounts receivable | −12 | −9 | −5 | |
| Inventory | −1 | 318,000 | −74,000 | |
| Prepaid expenses and other current assets | −1 | −2 | −1 | |
| Deferred commissions | −4 | −6 | −4 | |
| Other non-current assets | 251,000 | 409,000 | 213,000 | |
| Accounts payable | 6 | 399,000 | −286,000 | |
| Operating lease liabilities | −415,000 | −783,000 | −716,000 | |
| Accrued expenses and other current liabilities | 11 | 5 | 8 | |
| Deferred revenue | 6 | 5 | 1 | |
| Other non-current liabilities | 0 | 180,000 | 105,000 | |
| Net cash provided by (used in) operating activities | 18 | −34 | −50 | |
| Purchases of property and equipment | −1 | −596,000 | −416,000 | |
| Capitalized internal-use software costs | −5 | −3 | −3 | |
| Net cash used in investing activities | −6 | −4 | −3 | |
| Proceeds from issuance of Midcap term facility | 0 | 0 | 31 | |
| Payment of Midcap term facility issuance costs | 0 | 0 | −2 | |
| Proceeds from exercise of stock options | 9 | 3 | 2 | |
| Payment of deferred offering costs | −4 | −5 | −111,000 | |
| Payment of debt extinguishment costs | −1 | 0 | −623,000 | |
| Proceeds from initial public offering, net of underwriting discounts and commissions | 161 | 0 | 0 | |
| Net cash provided by (used in) financing activities | 133 | −1 | 179,000 | |
| Net increase (decrease) in cash and cash equivalents | 146 | −39 | −52 | |
| Interest | 2 | 4 | 4 | |
| Share-based compensation expense capitalized in internal-use software | 184,000 | 97,000 | 76,000 | |
| Unpaid deferred offering costs included in accounts payable | 0 | 131,000 | 23,000 | |
| Unpaid property and equipment included in accounts payable | 16,000 | 65,000 | 26,000 | |
| Conversion of redeemable convertible preferred stock in connection with initial public offering | 452 | 0 | 0 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Omada Health, Inc.'s CIK number?
Omada Health, Inc.'s SEC CIK number is 0001611115 (1611115). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Omada Health, Inc.'s SEC filings?
All of Omada Health, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Omada Health, Inc. last report earnings?
Omada Health, Inc. (OMDA) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001628280-26-032063). This is Omada Health, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Omada Health, Inc.'s most recent earnings 8-K?
Omada Health, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001628280-26-032063. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Omada Health, Inc.'s latest earnings 8-K →
Look up any company's CIK number →